Abstract
Cerebral ischemia is the third leading cause of death in industrialized countries and an important health system problem with no efficient treatment to date. The reduction in oxygen and glucose supply triggers a cascade of events such as excitotoxicity, oxidative stress, inflammation, apoptosis, and an adjustment of the gene expression program. The hypoxia inducible factor-1 (HIF-1) is a transcription factor that mediates the adaptive responses to the reduction in oxygen availability. HIF-1 activation in hypoxic conditions promotes the survival of cells through the induction of adaptive genes involved in glucose and energy production, glucose transport, cell proliferation, cell survival, iron homeostasis, erythropoiesis, angiogenesis and vascular reactivity. In recent years, biomedical research has focused on the oxygen regulated α subunit of HIF-1 as a potential therapy in medical events that involve hypoxic conditions. In this review we summarize current knowledge on the use of HIF-1α as a therapeutic target against cerebral ischemia through two different strategies: 1) the use of ischemic preconditioning to induce the HIF-1 pathway regulation, and 2) the pharmacological inhibition of prolyl and asparaginyl hydroxylases. Both strategies appear as attractive options for protection in ischemia in which signaling pathway activation could contribute to the establishment of tolerance in brain.
Keywords: Hypoxia inducible factor, ischemic preconditioning, prolyl hydroxylase, cerebral ischemia
Current Signal Transduction Therapy
Title: Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Volume: 4 Issue: 3
Author(s): Penelope Aguilera, Edgar Vazquez-Contreras, Carlos Daniel Gomez-Martínez and Maria Elena Chanez Cardenas
Affiliation:
Keywords: Hypoxia inducible factor, ischemic preconditioning, prolyl hydroxylase, cerebral ischemia
Abstract: Cerebral ischemia is the third leading cause of death in industrialized countries and an important health system problem with no efficient treatment to date. The reduction in oxygen and glucose supply triggers a cascade of events such as excitotoxicity, oxidative stress, inflammation, apoptosis, and an adjustment of the gene expression program. The hypoxia inducible factor-1 (HIF-1) is a transcription factor that mediates the adaptive responses to the reduction in oxygen availability. HIF-1 activation in hypoxic conditions promotes the survival of cells through the induction of adaptive genes involved in glucose and energy production, glucose transport, cell proliferation, cell survival, iron homeostasis, erythropoiesis, angiogenesis and vascular reactivity. In recent years, biomedical research has focused on the oxygen regulated α subunit of HIF-1 as a potential therapy in medical events that involve hypoxic conditions. In this review we summarize current knowledge on the use of HIF-1α as a therapeutic target against cerebral ischemia through two different strategies: 1) the use of ischemic preconditioning to induce the HIF-1 pathway regulation, and 2) the pharmacological inhibition of prolyl and asparaginyl hydroxylases. Both strategies appear as attractive options for protection in ischemia in which signaling pathway activation could contribute to the establishment of tolerance in brain.
Export Options
About this article
Cite this article as:
Aguilera Penelope, Vazquez-Contreras Edgar, Gomez-Martínez Daniel Carlos and Cardenas Elena Chanez Maria, Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia, Current Signal Transduction Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157436209789057458
DOI https://dx.doi.org/10.2174/157436209789057458 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Is Nephrogenic Systemic Fibrosis a Disease of Fibrocytes?
Current Rheumatology Reviews Fish Oil Supplementation: A Matter of DHA Enzymatic/Non-Enzymatic Oxidation Balance?
Current Nutrition & Food Science Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design Short-term High-Dose Effect of Lovastatin on Thrombolysis by rt-PA in a Human Whole-Blood in vitro Clot Model
Current Neurovascular Research The Impact of Hypertension as a Road to Heart Failure with Preserved Ejection Fraction: Diagnostic Value of Two-Dimensional Speckle Tracking Echocardiography for the Early Impairment of Left Atrial-Left Ventricular-Arterial Coupling
Current Hypertension Reviews GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Heme Oxygenase-1: A Potential Antihypertensive Target?
Current Hypertension Reviews Molecular Dissection of Renal Ischemia-Reperfusion: Oxidative Stress and Cellular Events
Current Medicinal Chemistry Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine Medicinal Agents in the Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry The Pharmacology of Diabetic Complications
Current Medicinal Chemistry Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology